Funding Source and Research Report Quality in Nutrition Practice-Related Research

Esther F. Myers¹*, J. Scott Parrott², Deborah S. Cummins¹, Patricia Splett³

1 Research and Strategic Business Development, American Dietetic Association, Chicago, Illinois, United States of America, 2 Department of Nutritional Sciences, University of Medicine and Dentistry of New Jersey, Newark, New Jersey, United States of America, 3 Splett and Associates, Stanchfield, Minnesota, United States of America

Abstract

Background: The source of funding is one of many possible causes of bias in scientific research. One method of detecting potential for bias is to evaluate the quality of research reports. Research exploring the relationship between funding source and nutrition-related research report quality is limited and in other disciplines the findings are mixed.

Objective: The purpose of this study is to determine whether types of funding sources of nutrition research are associated with differences in research report quality.

Design: A retrospective study of research reporting quality, research design and funding source was conducted on 2539 peer reviewed research articles from the American Dietetic Association's Evidence Analysis Library[®] database.

Results: Quality rating frequency distributions indicate 43.3% of research reports were rated as positive, 50.1% neutral, and 6.6% as negative. Multinomial logistic regression results showed that while both funding source and type of research design are significant predictors of quality ratings ($\chi 2 = 118.99$, p ≤ 0.001), the model's usefulness in predicting overall research report quality is little better than chance. Compared to research reports with government funding, those not acknowledging any funding sources, followed by studies with University/hospital funding were more likely to receive neutral vs positive quality ratings, OR = 1.85, P < 0.001 and OR = 1.54, P<0.001, respectively and those that did not report funding were more likely to receive negative quality ratings (OR = 4.97, P<0.001). After controlling for research design, industry funded research reports were no more likely to receive a neutral or negative quality rating than those funded by government sources.

Conclusion: Research report quality cannot be accurately predicted from the funding source after controlling for research design. Continued vigilance to evaluate the quality of all research regardless of the funding source and to further understand other factors that affect quality ratings are warranted.

Citation: Myers EF, Parrott JS, Cummins DS, Splett P (2011) Funding Source and Research Report Quality in Nutrition Practice-Related Research. PLoS ONE 6(12): e28437. doi:10.1371/journal.pone.0028437

Editor: Lise Lotte Gluud, Copenhagen University Hospital Gentofte, Denmark

Received June 3, 2011; Accepted November 8, 2011; Published December 6, 2011

Copyright: © 2011 Myers et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This research was supported by the North American Branch of the International Life Sciences Institute (www.ilsi.org/NorthAmerica). ILSI North America is a public, nonprofit scientific foundation that provides a forum to advance the understanding of scientific issues related to the nutritional quality and safety of the food supply. ILSI North America carries out its mission by sponsoring relevant research programs, professional education programs and workshops, seminars, and publications, as well as by providing a neutral forum for government, academic, and industry scientists to discuss and resolve scientific issues of common concern for the well-being of the general public. The programs of ILSI North America are supported primarily by the ILSI North America industry membership. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: emyers@eatright.org

Introduction

The use of the scientific method, traditions of the scientific community, and guidelines for research reporting serve to minimize research bias (defined as systematic deviation of research results or inferences from the truth) by individual or institutional interests [1]. As diagrammed in Figure 1, and reported by several authors, there is potential for bias to enter during the phase of primary research and when published studies are reviewed and synthesized for evidence analysis or review papers [2–6]. Studies investigating both non-nutrition-related and nutrition-related research have reported that published findings are likely to favor funder interests [7–14]. If this phenomenon were due to

researchers with a vested interest in the outcomes of the research being less rigorous in their adherence to standards of execution or reporting of scientific research and thus, consciously or unconsciously skewing their findings in favor of the preferred outcome, it would likely be reflected in lower research report quality ratings when research reports are reviewed and appraised for inclusion in systematic reviews.

Over the past 20 years, a growing amount of research literature has documented concerns regarding the influence of the funding source on research. Government agencies, journal publishers, and other research-focused organizations have developed guidelines for managing potential conflicts of interest or competing interests [15–18]. Data are mixed on the relationship between research



Figure 1. The research process and bias. doi:10.1371/journal.pone.0028437.g001

report quality and the funding source across healthcare disciplines [6,19–22]. Findings indicate that the relationship may vary by the segment of industry or subspecialty (e.g., knee construction, spine, trauma), the type of support (e.g., stock ownership, speaking engagements, or grant receipt), and the type of trial (e.g., drug trial, surgical trial, or other therapies) [7,10,11,23]. Similar data on nutrition-related topics are limited, and some studies have indicated that industry-funded research reports may be of equal or higher quality than non-industry-funded nutrition-related research [24–26]. Additional studies are needed to clarify whether the quality of the research report is related to the funding sources in nutrition-related research.

When conducting systematic reviews to provide guidance for clinical practice, research priorities, or to inform public policy, the methodology should yield results that articulate the level of confidence in the outcomes of the research. The Agency for Healthcare Research and Quality (AHRQ) report identified appraising quality of each research report as a key domain in systems that conduct systematic reviews [27].

The recently released Institute Of Medicine report with standards for systematic reviews for comparative effectiveness reviews of medical and surgical interventions identified the following elements for critically appraising each individual study: assessing risk of bias, relevance of the study's population, intervention, outcome measures, and the fidelity of the implementation of interventions [28]. The assessment of these elements is usually based on information in the published research report.

A variety of instruments for appraising the quality of research reports have been developed; however, no gold standard has been identified [29-31]. For this research, quality of the research report was determined by the presence or absence of threats to validity in the research question, subject selection or search strategy, comparable groups, withdrawals, blinding, appraisal, intervention/exposure, outcomes, analysis or data abstraction/synthesis, conclusion support, and/or likelihood of bias. The Quality Criteria Checklist (QCC), used to evaluate the quality of nutrition-related research reports included in this study had two versions: the Primary Research QCC [Figure 2 and 3] and the Review Research QCC [Figure 4]. Instruments published, in development, or in use before 2009 that were applicable to the topics and research designs included in the American Dietetic Association's (ADA's) Evidence Analysis Library (www.adaevidencelibrary.com) were reviewed. Current editions of Consolidated Standards for Reporting Trials (CONSORT), Strengthening of Reporting of Observational Studies in Epidemiology (STROBE), Transparent Reporting of Evaluations with Nonrandomized Designs (TREND) and the ADA Primary Research QCC were compared [32-38]. The following domains were represented in all four instruments: research question, subject selection or search strategy, comparable groups,

Figure 2. F	Prima	ry Research Quality Criteria Checklist (Page 1 of 2).						
QCC Domain	Prima	ary Research Quality Criteria Checklist						
	1. Wa	as the <u>research question</u> clearly stated?						
Research	1.1	Was the specific intervention(s) or procedure (independent variable(s)) identified?						
Question	1.2	Was the outcome(s) (dependent variable(s)) clearly indicated?						
	1.3	Were the target population and setting specified?						
	2. Wa	as the <u>selection</u> of study subjects/patients free from bias?						
Subject	2.1	Were inclusion/exclusion criteria specified (e.g., risk, point in disease progression, diagnostic or prognosis criteria), and with sufficient detail and without omitting criteria critical to the study?						
Selection	2.2	Were criteria applied equally to all study groups?						
	2.3	Were health, demographics, and other characteristics of subjects described?						
	2.4	Were the subjects/patients a representative sample of the relevant population?						
	3. We	ere study groups comparable?						
	3.1	Was the method of assigning subjects/patients to groups described and unbiased? (Method of randomization identified if RCT)						
	3.2	Were distribution of disease status, prognostic factors, and other factors (e.g., demographics) similar across study groups at baseline?						
Comparable	3.3	Were concurrent controls used? (Concurrent preferred over historical controls.)						
Groups	3.4	If cohort study or cross-sectional study, were groups comparable on important confounding factors and/or were preexisting differences accounted for by using appropriate adjustments in statistical analysis?						
	3.5	If case control study, were potential confounding factors comparable for cases and controls? (If case series with subjects serving as own control, this criterion is not applicable. Criterion may not be applicable in some sectional studies.)						
	3.6	If diagnostic test, was there an independent blind comparison with an appropriate reference standard (e.g., "gold						
		stanuaru):						
	4. Wa	as method of handling <u>withdrawals</u> described?						
	4. W a 4.1	as method of handling <u>withdrawals</u> described? Were follow up methods described and the same for all groups?						
Withdrawals	4. Wa 4.1 4.2	as method of handling <u>withdrawals</u> described? Were follow up methods described and the same for all groups? Was the number, characteristics of withdrawals (i.e., dropouts, lost to follow up, attrition rate) and/or response rate (cross-sectional studies) described for each group? (Follow up goal for a strong study is 80%.)						
Withdrawals	4. Wa 4.1 4.2 4.3	as method of handling withdrawals described? Were follow up methods described and the same for all groups? Was the number, characteristics of withdrawals (i.e., dropouts, lost to follow up, attrition rate) and/or response rate (cross-sectional studies) described for each group? (Follow up goal for a strong study is 80%.) Were all enrolled subjects/patients (in the original sample) accounted for?						
Withdrawals	4. Wa 4.1 4.2 4.3 4.4	as method of handling withdrawals described? Were follow up methods described and the same for all groups? Was the number, characteristics of withdrawals (i.e., dropouts, lost to follow up, attrition rate) and/or response rate (cross-sectional studies) described for each group? (Follow up goal for a strong study is 80%.) Were all enrolled subjects/patients (in the original sample) accounted for? Were reasons for withdrawals similar across groups?						
Withdrawals	4. Wa 4.1 4.2 4.3 4.4 4.5	as method of handling withdrawals described? Were follow up methods described and the same for all groups? Was the number, characteristics of withdrawals (i.e., dropouts, lost to follow up, attrition rate) and/or response rate (cross-sectional studies) described for each group? (Follow up goal for a strong study is 80%.) Were all enrolled subjects/patients (in the original sample) accounted for? Were reasons for withdrawals similar across groups? If diagnostic test, was decision to perform reference test not dependent on results of test under study?						
Withdrawals	4. Wa 4.1 4.2 4.3 4.4 4.5 5. Wa	as method of handling withdrawals described? Were follow up methods described and the same for all groups? Was the number, characteristics of withdrawals (i.e., dropouts, lost to follow up, attrition rate) and/or response rate (cross-sectional studies) described for each group? (Follow up goal for a strong study is 80%.) Were all enrolled subjects/patients (in the original sample) accounted for? Were reasons for withdrawals similar across groups? If diagnostic test, was decision to perform reference test not dependent on results of test under study? as blinding used to prevent introduction of bias?						
Withdrawals	4. Wa 4.1 4.2 4.3 4.4 4.5 5. Wa 5.1	as method of handling withdrawals described? Were follow up methods described and the same for all groups? Was the number, characteristics of withdrawals (i.e., dropouts, lost to follow up, attrition rate) and/or response rate (cross-sectional studies) described for each group? (Follow up goal for a strong study is 80%.) Were all enrolled subjects/patients (in the original sample) accounted for? Were reasons for withdrawals similar across groups? If diagnostic test, was decision to perform reference test not dependent on results of test under study? as blinding used to prevent introduction of bias? In intervention study, were subjects, clinicians/practitioners, and investigators blinded to treatment group, as appropriate?						
Withdrawals	 4. Wa 4.1 4.2 4.3 4.4 4.5 5.1 5.2 	as method of handling withdrawals described? Were follow up methods described and the same for all groups? Was the number, characteristics of withdrawals (i.e., dropouts, lost to follow up, attrition rate) and/or response rate (cross-sectional studies) described for each group? (Follow up goal for a strong study is 80%.) Were all enrolled subjects/patients (in the original sample) accounted for? Were reasons for withdrawals similar across groups? If diagnostic test, was decision to perform reference test not dependent on results of test under study? as blinding used to prevent introduction of bias? In intervention study, were subjects, clinicians/practitioners, and investigators blinded to treatment group, as appropriate? Were data collectors blinded for outcomes assessment? (If outcome is measured using an objective test, such as a lab value, this criterion is assumed to be met.)						
Withdrawals	 4. Wa 4.1 4.2 4.3 4.4 4.5 5. Wa 5.1 5.2 5.3 	as method of handling withdrawals described? Were follow up methods described and the same for all groups? Was the number, characteristics of withdrawals (i.e., dropouts, lost to follow up, attrition rate) and/or response rate (cross-sectional studies) described for each group? (Follow up goal for a strong study is 80%.) Were all enrolled subjects/patients (in the original sample) accounted for? Were reasons for withdrawals similar across groups? If diagnostic test, was decision to perform reference test not dependent on results of test under study? as blinding used to prevent introduction of bias? In intervention study, were subjects, clinicians/practitioners, and investigators blinded to treatment group, as appropriate? Were data collectors blinded for outcomes assessment? (If outcome is measured using an objective test, such as a lab value, this criterion is assumed to be met.) In cohort study or cross-sectional study, were measurements of outcomes and risk factors blinded?						
Withdrawals Blinding	4. Wa 4.1 4.2 4.3 4.4 4.5 5.1 5.2 5.3 5.4	as method of handling withdrawals described? Were follow up methods described and the same for all groups? Was the number, characteristics of withdrawals (i.e., dropouts, lost to follow up, attrition rate) and/or response rate (cross-sectional studies) described for each group? (Follow up goal for a strong study is 80%.) Were all enrolled subjects/patients (in the original sample) accounted for? Were reasons for withdrawals similar across groups? If diagnostic test, was decision to perform reference test not dependent on results of test under study? as blinding used to prevent introduction of bias? In intervention study, were subjects, clinicians/practitioners, and investigators blinded to treatment group, as appropriate? Were data collectors blinded for outcomes assessment? (If outcome is measured using an objective test, such as a lab value, this criterion is assumed to be met.) In cohort study or cross-sectional study, were measurements of outcomes and risk factors blinded? In case control study, was case definition explicit and case ascertainment not influenced by exposure status?						
Withdrawals	4. Wa 4.1 4.2 4.3 4.4 4.5 5.1 5.1 5.2 5.3 5.4 5.4	as method of handling withdrawals described? were follow up methods described and the same for all groups? Was the number, characteristics of withdrawals (i.e., dropouts, lost to follow up, attrition rate) and/or response rate (cross-sectional studies) described for each group? (Follow up goal for a strong study is 80%.) Were all enrolled subjects/patients (in the original sample) accounted for? Were reasons for withdrawals similar across groups? If diagnostic test, was decision to perform reference test not dependent on results of test under study? as blinding used to prevent introduction of bias? In intervention study, were subjects, clinicians/practitioners, and investigators blinded to treatment group, as appropriate? Were data collectors blinded for outcomes assessment? (If outcome is measured using an objective test, such as a lab value, this criterion is assumed to be met.) In cohort study or cross-sectional study, were measurements of outcomes and risk factors blinded? In case control study, was case definition explicit and case ascertainment not influenced by exposure status? In diagnostic study, were test results blinded to patient history and other test results?						
Withdrawals	4. Wa 4.1 4.2 4.3 4.4 4.5 5. Wa 5.1 5.2 5.3 5.4 5.4 6. We de	standard)? as method of handling withdrawals described? Were follow up methods described and the same for all groups? Was the number, characteristics of withdrawals (i.e., dropouts, lost to follow up, attrition rate) and/or response rate (cross-sectional studies) described for each group? (Follow up goal for a strong study is 80%.) Were all enrolled subjects/patients (in the original sample) accounted for? Were reasons for withdrawals similar across groups? If diagnostic test, was decision to perform reference test not dependent on results of test under study? as blinding used to prevent introduction of bias? In intervention study, were subjects, clinicians/practitioners, and investigators blinded to treatment group, as appropriate? Were data collectors blinded for outcomes assessment? (If outcome is measured using an objective test, such as a lab value, this criterion is assumed to be met.) In cohort study or cross-sectional study, were measurements of outcomes and risk factors blinded? In case control study, was case definition explicit and case ascertainment not influenced by exposure status? In diagnostic study, were test results blinded to patient history and other test results?						
Withdrawals	4. Wa 4.1 4.2 4.3 4.4 4.5 5.1 5.2 5.3 5.4 5.4 6. Wa de 6.1	as method of handling withdrawals described? Were follow up methods described and the same for all groups? Was the number, characteristics of withdrawals (i.e., dropouts, lost to follow up, attrition rate) and/or response rate (cross-sectional studies) described for each group? (Follow up goal for a strong study is 80%.) Were all enrolled subjects/patients (in the original sample) accounted for? Were reasons for withdrawals similar across groups? If diagnostic test, was decision to perform reference test not dependent on results of test under study? as blinding used to prevent introduction of bias? In intervention study, were subjects, clinicians/practitioners, and investigators blinded to treatment group, as appropriate? Were data collectors blinded for outcomes assessment? (If outcome is measured using an objective test, such as a lab value, this criterion is assumed to be met.) In cohort study or cross-sectional study, were measurements of outcomes and risk factors blinded? In case control study, was case definition explicit and case ascertainment not influenced by exposure status? In diagnostic study, were test results blinded to patient history and other test results? ere intervention/therapeutic regimens/explosure factor or procedure and any comparison(s) described in tail? Were intervention trial, were protocols described for all regimens studied?						
Withdrawals	4. Wa 4.1 4.2 4.3 4.4 4.5 5.1 5.2 5.3 5.4 5.4 6. Wa de 6.1 6.2	as method of handling withdrawals described? Were follow up methods described and the same for all groups? Was the number, characteristics of withdrawals (i.e., dropouts, lost to follow up, attrition rate) and/or response rate (cross-sectional studies) described for each group? (Follow up goal for a strong study is 80%.) Were all enrolled subjects/patients (in the original sample) accounted for? Were reasons for withdrawals similar across groups? If diagnostic test, was decision to perform reference test not dependent on results of test under study? as blinding used to prevent introduction of bias? In intervention study, were subjects, clinicians/practitioners, and investigators blinded to treatment group, as appropriate? Were data collectors blinded for outcomes assessment? (If outcome is measured using an objective test, such as a lab value, this criterion is assumed to be met.) In cohort study or cross-sectional study, were measurements of outcomes and risk factors blinded? In case control study, was case definition explicit and case ascertainment not influenced by exposure status? In diagnostic study, were test results blinded to patient history and other test results? ere intervention/therapeutic regimens/explosure factor or procedure and any comparison(s) described in tail? Were intervention trial, were protocols described for all regimens studie? In RCT or other intervention trial, were protocols described for all regimens studie? In observational study, were interventions, study settings, and clinicians/pr						
Withdrawals Blinding	4. Wa 4.1 4.2 4.3 4.4 4.5 5.1 5.2 5.3 5.4 5.4 5.4 6. We de 6.1 6.2 6.3	standard): as method of handling withdrawals described? Were follow up methods described and the same for all groups? Was the number, characteristics of withdrawals (i.e., dropouts, lost to follow up, attrition rate) and/or response rate (cross-sectional studies) described for each group? (Follow up goal for a strong study is 80%.) Were all enrolled subjects/patients (in the original sample) accounted for? Were reasons for withdrawals similar across groups? If diagnostic test, was decision to perform reference test not dependent on results of test under study? as blinding used to prevent introduction of bias? In intervention study, were subjects, clinicians/practitioners, and investigators blinded to treatment group, as appropriate? Were data collectors blinded for outcomes assessment? (If outcome is measured using an objective test, such as a lab value, this criterion is assumed to be met.) In cohort study or cross-sectional study, were measurements of outcomes and risk factors blinded? In case control study, was case definition explicit and case ascertainment not influenced by exposure status? In diagnostic study, were test results blinded to patient history and other test results? The intervention/therapeutic regimens/explosure factor or procedure and any comparison(s) described in tail? Were intervention trial, were protocols described for all regimens studied? In RCT or other intervention trial, were protocols described for all regimens studied? In observational study, were						
Withdrawals Blinding Intervention/ Exposure	4. Wa 4.1 4.2 4.3 4.4 4.5 5.1 5.2 5.3 5.4 5.4 5.4 6.1 6.2 6.3 6.4	standard (): as method of handling withdrawals described? Were follow up methods described and the same for all groups? Was the number, characteristics of withdrawals (i.e., dropouts, lost to follow up, attrition rate) and/or response rate (cross-sectional studies) described for each group? (Follow up goal for a strong study is 80%.) Were all enrolled subjects/patients (in the original sample) accounted for? Were reasons for withdrawals similar across groups? If diagnostic test, was decision to perform reference test not dependent on results of test under study? as blinding used to prevent introduction of bias? In intervention study, were subjects, clinicians/practitioners, and investigators blinded to treatment group, as appropriate? Were data collectors blinded for outcomes assessment? (If outcome is measured using an objective test, such as a lab value, this criterion is assumed to be met.) In cohort study or cross-sectional study, were measurements of outcomes and risk factors blinded? In case control study, was case definition explicit and case ascertainment not influenced by exposure status? In diagnostic study, were test results blinded to patient history and other test results? ere intervention/therapeutic regimens/explosure factor or procedure and any comparison(s) described in tail? Were intervention trial, were protocols described for all regimens studie? In RCT or other intervention rial, were protocols described for all regimens studie? In observational study, were in						
Withdrawals Blinding Intervention/ Exposure	4. Wa 4.1 4.2 4.3 4.4 4.5 5.1 5.2 5.3 5.4 5.4 6. Wa de 6.1 6.2 6.3 6.4 6.5	as method of handling withdrawals described? Were follow up methods described and the same for all groups? Was the number, characteristics of withdrawals (i.e., dropouts, lost to follow up, attrition rate) and/or response rate (cross-sectional studies) described for each group? (Follow up goal for a strong study is 80%.) Were all enrolled subjects/patients (in the original sample) accounted for? Were reasons for withdrawals similar across groups? If diagnostic test, was decision to perform reference test not dependent on results of test under study? as blinding used to prevent introduction of bias? In intervention study, were subjects, clinicians/practitioners, and investigators blinded to treatment group, as appropriate? Were data collectors blinded for outcomes assessment? (If outcome is measured using an objective test, such as a lab value, this criterion is assumed to be met.) In cohort study, were test results blinded to patient history and other test results? In diagnostic study, were test results blinded to patient history and other test results? In diagnostic study, were intervention s, study settings, and clinicians/provider described? In RCT or other intervention frial, were protocols described for all regimens studied? In observational study, were interventions, study settings, and clinicians/provider described? Was the intensity and duration of the intervention or exposure factor sufficient to produce a meaningful effect? Was the intensity and duration of the intervent						
Withdrawals Blinding Intervention/ Exposure	4. Wa 4.1 4.2 4.3 4.4 4.5 5.1 5.2 5.3 5.4 5.4 5.4 6. Wa de 6.1 6.2 6.3 6.4 6.5 6.6	as method of handling withdrawals described? Were follow up methods described and the same for all groups? Was the number, characteristics of withdrawals (i.e., dropouts, lost to follow up, attrition rate) and/or response rate (cross-sectional studies) described for each group? (Follow up goal for a strong study is 80%.) Were all enrolled subjects/patients (in the original sample) accounted for? Were reasons for withdrawals similar across groups? If diagnostic test, was decision to perform reference test not dependent on results of test under study? as blinding used to prevent introduction of bias? In intervention study, were subjects, clinicians/practitioners, and investigators blinded to treatment group, as appropriate? Were data collectors blinded for outcomes assessment? (If outcome is measured using an objective test, such as a lab value, this criterion is assumed to be met.) In cohort study, were set results blinded to patient history and other test results? In diagnostic study, were test results blinded to patient history and other test results? In diagnostic study, were intervention s, study settings, and clinicians/provider described? In RCT or other intervention frial, were protocols described for all regimens studied? In observational study, were interventions, study settings, and clinicians/provider described? Was the intensity and duration of the intervention or exposure factor sufficient to produce a meaningful effect? Was the intensity and duration of the interventi						
Withdrawals Blinding Intervention/ Exposure	4. Wa 4.1 4.2 4.3 4.4 4.5 5.1 5.2 5.3 5.4 5.4 5.4 6.1 6.2 6.3 6.4 6.5 6.6 6.6 6.7	as method of handling withdrawals described? Were follow up methods described and the same for all groups? Was the number, characteristics of withdrawals (i.e., dropouts, lost to follow up, attrition rate) and/or response rate (cross-sectional studies) described for each group? (Follow up goal for a strong study is 80%.) Were all enrolled subjects/patients (in the original sample) accounted for? Were reasons for withdrawals similar across groups? If diagnostic test, was decision to perform reference test not dependent on results of test under study? as appropriate? In intervention study, were subjects, clinicians/practitioners, and investigators blinded to treatment group, as appropriate? Were data collectors blinded for outcomes assessment? (If outcome is measured using an objective test, such as a lab value, this criterion is assumed to be met.) In cohort study or cross-sectional study, were measurements of outcomes and risk factors blinded? In diagnostic study, was case definition explicit and case ascertainment not influenced by exposure status? In diagnostic study, were test results blinded to patient history and other test results? The intervention/therapeutic regimens/explosure factor or procedure and any comparison(s) described in tail? Were intervention trial, were protocols described for all regimens studied? In observational study, were interventions or exposure factor sufficient to produce a meaningful effect? Was the intensity and duration of the intervention or exposure factor sufficient to produce a						

Figure 2. Sample of the American Dietetic Association's primary research quality criteria checklist. doi:10.1371/journal.pone.0028437.g002

Figure 3.	Prima	ry Research Quality Criteria Checklist (Page 2 of 2).					
QCC Domain	Prima	ary Research Quality Criteria Checklist					
	7. We	ere outcomes clearly defined and the measurements valid and reliable?					
	7.1	Were primary and secondary endpoints described and relevant to the question?					
	7.2	Were nutrition measures appropriate to question and outcomes of concern?					
	7.3	Was the period of follow-up long enough for important outcome(s) to occur?					
Outcomes	7.4	Were the observations and measurements based on standard, valid, and reliable data collection instruments/tests/ procedures?					
	7.5	Was the measurement of effect at an appropriate level of precision?					
	7.6	Were other factors accounted for (measured) that could affect outcomes?					
	7.7	Were the measurements conducted consistently across groups?					
	8. Wa	as the statistical analysis appropriate for the study design and type of outcomes indicators?					
	8.1	Were statistical analyses adequately described the results reported appropriately?					
	8.2	2 Were correct statistical tests used and assumptions of test not violated?					
	8.3	Were statistics reported with levels of significance and/or confidence intervals?					
Analysis	8.4	Was "intent to treat" analysis of outcomes done (and as appropriate, was there an analysis of outcomes for those maximally exposed or a dose-response analysis)?					
	8.5	Were adequate adjustments made for effects of confounding factors that might have affected the outcomes (e.g., multivariate analyses)?					
	8.6	Was clinical significance as well as statistical significance reported?					
	8.7	If negative findings, was a power calculation reported to address type 2 error?					
	9. Ar	e <u>conclusions supported by results</u> with biases and limitations taken into consideration?					
Conclusion	9.1	Is there a discussion of findings?					
oupport	9.2	Are biases and study limitations identified and discussed?					
	10. Is bias due to study's <u>funding or sponsorship</u> unlikely?						
Likelihood	10.1	Were sources of funding and investigators' affiliations described?					
	10.2	Was there no apparent conflict of interest?					
MINUS/NEGA If most (six or the Evidence of	TIVE (more) Quality	-) of the answers to the above validity questions are "No," the review should be designated with a minus (-) symbol on c Checklist					
NEUTRAL (Ø)	• • • • • • • • • • • • • • • • • • •					

If the answer to any of the first four validity questions (1-4) is "No," but other criteria indicate strengths, the review should be designated with a neutral (\emptyset) symbol on the Evidence Worksheet.

PLUS/POSITIVE (+)

If most of the answers to the above validity questions are "Yes" (must include criteria 1,2,3, and 4), the report should be designed with a plus (+) symbol on the Evidence Worksheet.

Figure 3. Sample of the American Dietetic Association's primary research quality criteria checklist. doi:10.1371/journal.pone.0028437.g003

uoi.10.137 1/journal.pone.0020437.9003

withdrawals, blinding, intervention/exposure, outcomes, analysis or data abstraction/synthesis, conclusion support, and likelihood of bias. The levels of specificity, organization and interpretation of domain by research design varied among the instruments. Since three of the instruments were specific to a particular research design, the interpretation of the domains varied among the instruments, particularly in the domains for comparable groups, blinding, and intervention/exposure. The Primary Research QCC is a tool with different questions within domains that are applicable to differing research designs.

The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) [updated QUORUM instrument], Meta-analysis of Observational Studies in Epidemiology (MOOSE), A Measurement Tool to Assess Systematic Reviews (AMSTAR) and the ADA Review Research QCC were also compared [38–42]. The major domains of research question, subject selection or search strategy, appraisal, intervention/ exposure, outcomes, data abstraction/synthesis, results, conclusion support and likelihood of bias were represented in all instruments. There were varying levels of specificity among the instruments within each domain and differing organization of the specific items being rated. The STROBE, MOOSE, and ADA's Review Research QCC were most similar in content.

Description of Evidence Analysis Process on Nutrition-Related Topics

ADA has been conducting systematic reviews for nutritionrelated issues since 2000 following a detailed evidence analysis

Figure 4. Review Quality Criteria Checklist.						
QCC Domain	Review Quality Criteria Checklist					
Research Question	1. Was the question for the review clearly focused and appropriate?					
Search Strategy	2. Was the search strategy used to locate relevant studies compre- hensive? Were the databases searched and the search terms used described?					
Selection	3. Were explicit methods used to select studies to include in the re- view? Were inclusion/exclusion criteria specified and appropriate? Were selection methods unbiased?					
Appraisal	4. Was there an appraisal of the quality and validity of studies in- cluded in the review? Were appraisal methods specified, appropriate, and reproducible?					
Intervention/ Exposure	5. Were specific treatments/interventions/exposures described? Were treatments similar enough to be combined?					
Outcome	6. Was the outcome of interest clearly indicated? Were other potential harms and benefits considered?					
Data Abstraction/ Synthesis Process	7. Were processes for data abstraction, synthesis, and analysis described? Were they applied consistently across studies and groups? Was there appropriate use of qualitative and/or quantita- tive synthesis? Was variation in findings among studies analyzed? Were heterogeneity issued considered? If data from studies were aggregated for meta-analysis, was the procedure described?					
Results	8. Are the results clearly presented in narrative and/or quantitative terms? If summary statistics are used, are levels of significance and/or confidence intervals included?					
Conclusion Support	9. Are conclusions supported by results with biases and limitations taken into consideration? Are limitations of the review identified and discussed?					
Liklihood of Bias	10. Was bias due to the review's funding or sponsorship unlikely?					
MINUS/NEGATIVE (-) If most (six or more) of the answers to the above validity questions are "No," the review should be designated with a minus (-) symbol on the Evidence Worksheet						
NEUTRAL (Ø) If the answer to any of t strengths, the review sh	NEUTRAL (Ø) If the answer to any of the first four Validity questions (1-4) is "No," but other criteria indicate strengths, the review should be designated with a neutral (Ø) symbol on the Evidence Worksheet					
PLUS/POSITIVE (+) If most of the answers a and 4), the report shou	PLUS/POSITIVE (+) If most of the answers to the above validity questions are "Yes" (must include criteria 1, 2, 3, and 4) the report should be designated with a plus (+) symbol on the Evidence Worksheet					

Figure 4. Sample of the American Dietetic Association's review research quality criteria checklist. doi:10.1371/journal.pone.0028437.g004

process that includes a quality appraisal of every included research report [38]. QCCs developed for the appraisals were based on the AHRQ criteria [38]. Research reports included in the nutritionrelated systematic reviews are identified through searches of online electronic databases, supplemented by hand reviews of journals, and by examination of bibliographies, as necessary, following a search plan developed by a work group with expertise in the specific nutrition topic being evaluated. Identified research reports are checked to verify that each one met the pre-established eligibility criteria. Trained analysts then reviewed each research report and abstracted pertinent information into an online worksheet. A QCC, either for primary research [Figures 2 and 3] or reviews of research [Figure 4], was used to appraise the research report and determine an overall research quality rating of positive (higher quality), neutral, or negative (lower quality). The overall quality ratings indicated the quality of the research design and implementation of the research as shown in the research report, but did not indicate the direction or nature of the findings. Ratings to the sub-questions were made according to the research design and used to formulate the rating for the domain question. Worksheets and QCC responses were reviewed by a lead analyst, and following approval by the expert workgroup, were approved for inclusion in the systematic review. A full description of the appraisal process is available on the Evidence Analysis Library website(www.adaevidencelibrary.com) and in excerpts from the *Evidence Analysis Manual* which can be found in the supplemental material for this article [Supporting Information S1]. As of February 2009, over 2,600 abstracted research reports in 23 nutrition topics of priority interest to the field (e.g., management of hypertension, adult and pediatric obesity, diabetes, disorders of lipid metabolism, non-nutritive sweeteners, and nutrition counseling) were included in the online evidence analysis library [Figure 5]. Additional descriptions of the nutrition-related topics included in the sample are found in the supplemental materials for this article [Supporting Information S2].

The availability of an existing evidence analysis database that included a large number of nutrition-related research report quality appraisals provided a unique opportunity to investigate the relationships between funding source and research report quality. The aim of this cross-sectional study was to determine whether funding source of nutrition and dietetics practice-related research, particularly industry-funded research, was associated with differences in research report quality, and further, if these associations varied across different types of research design. In this study,

Figure 5. Number of nutrition-related research reports and questions for each topic in the Evidence Analysis Library database on February 2009.¹

Торіс	Number of PICO questions	Number of Research Reports (abstracted articles/worksheets) ²
Adult Weight Management	16 questions	209
Breastfeeding	3 questions	38
Childhood Overweight	34 questions	227
Chronic Kidney Disease	5 questions	18
Chronic Obstructive Pulmonary Disease (COPD)	10 questions	84
Critical Illness	83 questions	135
Diabetes 1 and 2	16 questions	225
Disorders of Lipid Metabolism (DLM)	77 questions	239
Energy Expenditure	146 questions	192
Fiber	4 questions	50
Nutrition Supplementation	7 questions	44
Gestational Diabetes	13 questions	125
Celiac Disease	12 questions	112
Heart Failure	16 questions	35
HIV/AIDS	4 questions	33
Hydration	8 questions	77
Hypertension	15 questions	100
Medical Nutrition Therapy Effectiveness	5 questions	31
Non-nutritive sweeteners	12 questions	65
Nutrition Counseling	25 questions	81
Nutrition in Athletic Performance	5 questions	111
Nutrition Screening	2 questions	1
Oncology	111 questions	120
Pediatric Weight Management	52 questions	66
Sodium	3 questions	6
Spinal Cord Injury	12 questions	67
Unintended Weight Loss	5 questions	22
Vegetarian Nutrition	29 questions	59
29 Topics	732 questions	2573 ²
¹ The ADA Evidence Analysis Library da unique abstracted research reports (we material includes key words for each of ² Some worksheets were used in more	atabase contained 29 topics, orksheets) with quality check f the projects. than one project.	732 questions and 2539 lists. Supplemental

Figure 5. Number of nutrition-related research reports and questions for each topic in the Evidence Analysis Library database on February 2009.

doi:10.1371/journal.pone.0028437.g005

"quality" refers to a set of expectations for the design, implementation, and reporting of research that are believed to reduce the risk of bias and support the validity of findings. Quality is assessed based on information available in published research reports utilizing checklists that incorporate widely accepted domains of rigorous scientific investigation and research synthesis. Thus, the term *research report quality* is used.

Materials and Methods

Sample

All research report appraisal forms already in the Evidence Analysis Library as of February 2009 were screened for complete and valid answers to the ten-item QCC. Research report appraisals were already included in the library database through the process described in the introduction and more completely described in the supplementary material and on the website. Out of a total of 2,632 entries, 93 were excluded resulting in a sample size of 2,539 research reports with overall quality ratings and completed QCCs.

Variables

This study used the following variables: overall quality rating (positive, neutral, or negative), individual QCC domain responses (yes, no, unclear or not applicable), type of research (intervention, observation, and review), and funding source (government, industry, multiple, university/hospital, non-profit, and not reported).

Data Collection

All data variables, with one exception, already existed in the database from previously completed systematic reviews. The funding source for each research report was the only missing data needed to complete this study. A consolidated report was created from the library database that extracted citations, research design, overall quality rating, and responses to individual QCC domain ratings. For this study, the published research reports included in the sample were examined to identify funding sources from the acknowledgements, report text, or author affiliations. The funders' names were recorded and, if necessary, the type of organization was determined after reviewing the respective organization's website. Research assistants, with no knowledge of the previously assigned quality ratings, classified the research reports into six funding source categories: government, industry, multiple, university/hospital, non-profit, and not reported. If funding from more than one funding source category was recorded, the research report was placed in the multiple funders category; however, if the research reported two or more funders from the same category (e.g., two non-profits), the report was classified in the same category.

The research design recorded in the abstract worksheet during the evidence analysis process was used to assign each research report into one of three categories for research-type: intervention, observation, and review. The intervention category included randomized controlled trials, non-randomized trials, and noncontrolled trials. The observation category included crosssectional, cohort, case-control, and other observational research. The review category included narrative reviews, systematic reviews, and meta-analyses.

The QCC data extracted from the library database were combined with the newly created data for assigned funding source and research-type category created for data analysis.

Analyses

Given the conflicting research on the quality of research reports funded by industry sources, we hypothesized that after research design was taken into account, there would be no difference in overall quality rating between those research reports funded by government sources and those funded by industry sources. Secondarily, we sought to quantify the effect size of the funding source/research report quality relationship in order to determine whether detected relationships were meaningful, because findings of statistical significance do not equate to practically meaningful differences (referred to as "clinical significance" in clinical settings), particularly in a large data set [43].

An a priori power calculation based on effect sizes gleaned from a similar study (at $\alpha = 0.05$ and a power of 0.8) indicated that a sample size of 241 industry-funded research reports was needed for a chi-square analysis [44]. However, because of differences in methodologies of the previous study and our current study, this value was used as an approximation. A post hoc test of power was calculated to examine the difference in proportion in quality ratings between government and industry funding sources and revealed an achieved power of 0.99.

Descriptive statistics are reported using frequency distributions (n, %). In addition, to determine whether research design should be included in the model as a confounder, chi-square tests were used to examine possible associations between the research-type category and the funding source and the research report quality, respectively. A comparison of the funding source and the type of research of the 93 excluded research reports verified that they were not significantly different from the total sample (funding source: $\chi^2 = 3.53$, P = 0.474; research-type category: $\chi^2 = 4.22$, P = 0.121).

We used hierarchical multinomial logistic regression to model and test predictors of research report quality rating, with both the funding source and research-type category serving as independent variables [45]. The term government was set as the reference category for funding source, and *intervention* became the reference category for the research type. These reference categories were selected because government funding is typically viewed as more credible, and interventions that include randomized controlled trials (RCT) are considered the gold standard of research design. Changes in -2 log likelihood were used to determine whether each independent variable contributed significantly to the model, and differences between categories of the independent variables were tested using the Wald statistic [46]. The effect size of individual categories is reported using odds ratios (ORs). The Nagelkerke pseudo R^2 was used as a metric of effect size of the overall model. In order to obtain further insights, three modified versions of the above analysis were carried out. First, the model was also run with other reference standards (e.g., industry and review, and government and observation), and these analyses did not provide additional insights. Second, the same analysis was repeated except with review design studies dropped from the analysis. Finally, RCT design studies were separated from other types of intervention trial designs and we tested for an association between study reporting quality and funder type within each different type of study design. Because of small cell size, a chi-square test of independence rather than a logistic regression was used for this final analysis.

An a priori alpha value was set at $P \le 0.05$. SPSS software version 17.0 (SPSS Corporation, Chicago, Illinois) was used for all analyses.

A series of secondary analyses were done to describe ratings for individual quality items for reports of studies with intervention and observational study designs and to examine the association of individual quality criteria with funding source; and to investigate the possible impact of review articles on the research findings conclusions. Chi-square tests were used to confirm expectations that the four questions required for positive quality rating were associated with quality ratings. Because of the QCC instructions [Figure 2, 3 and 4], we anticipated that questions 2, 3, 6 and 7 would be significant predictors of positive quality.

Multinomial logistic regression analyses were used to determine the relative importance of each question's contribution to overall quality rating. Positive quality rating was set as the reference category for the first model (neutral or negative quality compared to positive) and neutral quality was set as the reference category for the second analysis in order to determine which questions predicted negative compared to neutral quality. "No" and "unclear" responses were collapsed into "no" for this analysis.

Because of a complete separation of data for questions 2, 3, 6 and 7 (since these questions were required for an overall positive rating), we repeated the first analysis (positive versus neutral and negative) with a reduced model (omitting these four questions). Odds ratios and 95% confidence intervals around the ORs were calculated to determine which QCC questions best predicted quality rating among intervention and observational studies.

Results

Overall Quality Ratings

Descriptive statistics showing the research-type and funding sources are shown in Table 1. The most common research-type categories in the sample were intervention (51.6%) and observation (39%), with the review type comprising only 9.4% of the research reports. The multiple funders category (n = 762, 30%)had the largest number of research reports, followed by the university/hospital category (n = 665, 26.2%). The multiple funders category included 353 research reports (45%) that had industry as one of the multiple funders; and 183 of those research reports included a combination of government and industry funding. The industry funder category included food manufacturing companies (n = 100), pharmaceutical companies (n = 81), commodity groups, (n = 13), and other funders (n = 17). The research-type category was significantly associated with the funding source ($\chi^2 = 126.95$, $P \le 0.001$). Research reports funded by government and university/hospital funding sources were more evenly divided between the categories of intervention and observation, whereas a higher proportion of industry-funded research reports was found in the intervention category. Reviews

were more commonly funded by non-profits, followed by university/hospital sources.

The overall distribution of quality ratings for research reports was 43.3% positive, 50.1% neutral, and 6.6% negative. As shown in Table 2, the proportion of quality ratings differed significantly by research type ($\chi^2 = 89.64$, P < 0.001).

Table 3 shows the results of the multinomial logistic regression to test the hypothesis that funding source predicts research report quality when controlling for the research type category. Although the model combining both funding source and research type met the criteria for statistical significance ($\chi^2 = 118.99$, P<0.001), the effect size is very small (pseudo $R^2 = 0.055$). Based on -2 loglikelihood statistics, both independent variables, funding source and research design type, contribute significantly to the model $(\chi^2 = 52.89, P < 0.001; \text{ and } \chi^2 = 62.81, P < 0.001, \text{ respectively}).$ Although both independent variables were significant predictors of research report quality, the predictive accuracy of the model was, overall, little better than chance. Based on a cross-classification of predicted quality by actual quality, the model only correctly classified 50.9% of research reports. The model predicting research report quality from funding source and research type correctly classified none of the negative quality research reports, 70% of the neutral quality research reports, and only 36.6% of the positive quality research reports.

Only two funding sources (university/hospital and not reported) were significantly more likely to receive an overall neutral quality rating than research reports with government-only funding (OR = 1.54, P<0.001; and OR = 1.85, P<0.001, respectively). After controlling for research type (P=0.069), results indicated that research reports funded by industry sources were no more likely to receive a neutral quality rating than those funded by government sources. With respect to a negative quality rating, only research reports in which the funding source was not reported were more likely than government-funded research reports to receive a negative quality rating (OR = 4.97, P<0.001). Except for very slight differences in the OR values, results were identical for models that included only intervention and observational research and excluded review design studies. Thus, the relationship between funding source and research report quality was not a result of including review design studies in the model.

Review research type reports were more likely to receive both neutral (P < 0.05) and negative (P < 0.001) quality ratings than

Table 1. Nutrition-related research reports by funding source and type of research.¹

Type of Research								
	Intervention ²		Observation ³		Review ⁴		Total	
Funding Source	n	(%)	n	(%)	n	(%)	n	(%)
Government	249	(48.9)	229	(45.0)	31	(6.1)	509	(20.0)
Industry	147	(73.9)	35	(17.6)	17	(8.5)	199	(7.9)
Multiple funders	429	(56.3)	288	(37.8)	45	(5.9)	762	(30.0)
University/hospital	313	(47.4)	268	(40.3)	84	(12.6)	665	(26.2)
Non-profit	77	(46.1)	52	(31.1)	38	(22.8)	167	(6.6)
Funder not reported	95	(40.1)	119	(50.2)	23	(9.8)	237	(9.3)
Total	1310	(51.6)	991	(39.0)	238	(9.4)	2539	(100.0)

¹Funding source and type of research are significantly associated ($\chi^2 = 126.95$, P<0.001).

²Intervention research includes research designs such as randomized (individual and group), non-randomized, and non-controlled trials.

³Observation research includes cross-sectional, cohort, case control, time series, trend, and non-comparative studies.

⁴Review research includes narrative and systematic reviews and meta-analyses.

doi:10.1371/journal.pone.0028437.t001

Table 2. Nutrition-related research reports by type of research and quality rating.¹

Quality Rating								
	Positive ²		Neutral ³		Negative ⁴		Total	
Type of Research	N	(%)	N	(%)	n	(%)	n	(%)
Intervention	575	(43.9)	663	(50.6)	72	(5.5)	1310	(51.6)
Observation	454	(45.8)	490	(49.5)	47	(4.7)	991	(39.0)
Review	71	(29.8)	118	(49.6)	49	(20.6)	238	(9.4)
Total	1100	(43.3)	1271	(50.1)	168	(6.6)	2539	(100.0)

¹Quality rating and type of research are significantly associated ($\chi^2 = 89.64$, P<0.001).

²A positive quality rating requires that four critical quality criteria (selection of subjects free of bias, study groups comparable, intervention or procedure and intervening factors described, and outcomes clearly defined and measured using valid and reliable methods) are met and at least one additional checklist item is met.
³A neutral quality rating is assigned when responses to the four critical quality criteria do not indicate that the research report is exceptionally strong.

⁴A negative quality rating is assigned when six or more of the 10 checklist items are not met.

doi:10.1371/journal.pone.0028437.t002

intervention research type reports. Observation research-type reports were no more likely to receive either a neutral or a negative quality rating than intervention research type reports (P=0.367 and P=0.200, respectively).

In the final analysis, RCT design studies were separated from other types of intervention trials (resulting in four research design types: review, observational, RCT, and other intervention types). There was no statistically significant association between funder type and research reporting quality within either review ($\chi^2 = 17.78$, P = 0.059) or observational ($\chi^2 = 17.69$, P = 0.060) study types. There was a significant association between funder type and reporting quality within RCT designs ($\chi^2 = 49.35$, P < 0.001). A valid chi-square test was not possible within other intervention design studies because more than 20% of cells contained an expected value of <5. Within the RCT design, studies funded by multiple funders were significantly less likely to be negative quality while studies where funding was not reported were significantly more likely to receive a negative quality rating.

Individual QCC Domain Responses in Primary Research Reports

In our sample of primary research reports, all of the QCC domain questions received a "yes" response in at least 50% of the articles, with only the following two questions receiving this answer in less than 70% of articles: whether subject selection was free from bias (Q2, 66.52%) and whether blinding was used (Q5, 50.31%). These three QCC domain questions received responses of "unclear" in at least 10% of the articles: whether subject selection was free from bias (Q2, 23.33%), whether study groups were comparable (Q3, 11.79%), and whether blinding was used (Q5, 11.84%).

Table 3. Predictors of nutrition-related research manuscripts receiving neutral and negative quality ratings versus positive ratings compared with government-funded intervention research.¹

	Likelihood of Quality Rating Versus Positive Quality						
	Neutral		Negative				
Factor	OR	95% CI of OR	OR	95% CI of OR			
Funder							
Government (reference category)	1.00	—	1.00	_			
Industry	1.38	0.98–1.95 ²	1.90	0.95-3.81			
Multiple funders	1.10	0.87–1.38	0.98	0.56–1.71			
University/Hospital	1.54 ³	1.21–1.96	1.62	0.95–2.76			
Non-profit	1.17	0.81-1.68	1.14	0.53-2.45			
Not reported	1.85 ³	1.32–2.59	4.97 ³	2.76-8.95			
Type of research							
Intervention (reference category)	1.00	—	1.00	_			
Observation	0.92	0.78-1.10	0.77	0.52-1.15			
Review	1.38 ⁴	1.00–1.90	5.26 ³	3.34-8.28			

Abbreviations: CI, confidence interval; OR, odds ratio.

¹Statistical significance of the model combining funding and type of research to predict quality ratings ($\chi^2 = 118.99$, P < 0.001, pseudo $R^2 = 0.055$).

²Confidence intervals containing the value of 1.0 do not indicate a statistically significant difference between the response and reference category.³⁷

³P<0.001, based on the Wald statistic.

 $^{4}P < 0.05$, based on the Wald statistic.

doi:10.1371/journal.pone.0028437.t003

Table 4 shows the domains from the primary research QCC, which were more likely to have a "no" or "unclear" response by funder category reflecting a weakness, or less likely to receive either "unclear" or "no" reflecting a strength in the primary research reports at the $P \le 0.05$ significance level. The funding categories with strengths in research report quality are: multiple funders (4 strengths), government (3 strengths), and non-profit (2 strengths). The funding categories with weakness are no funding reported (7 weaknesses), university/hospital (5 weaknesses), industry (1 weakness), and government (1 weakness). Only two of the criteria identified as strengths were repeated in more than one funding category. Both multiple funders and government had significantly fewer "no" or "unclear" responses on Question 9 (conclusion support) and Question 10 (likelihood of bias due to funding). University/hospital and not reported funding categories both showed weaknesses in Question 3 (group comparability), Question 6 (intervention process), and Question 8 (analysis). Government and not reported funding categories both received a higher proportion of responses as "no" or "unclear" for Question 5 (blinding). University/hospital and industry both reported a higher proportion of responses as "no" or "unclear" to Question 10 (likelihood of bias due to funding). In addition to identifying these responses by funding category, an additional analysis was completed to determine if Question 10.2 (likelihood of conflict of interest) was sufficient to predict the overall quality rating. When evaluating all overall quality ratings together, the rating for Question 10 (likelihood of bias due to funding) was not a statistically significant predictor (P > 0.05) of either an overall neutral or negative quality rating compared to a positive overall quality rating.

Discussion

In this study, funding source was found to provide only minimal information about the quality of the research report. While the statistical results support the hypothesis that an association exists in nutrition-related research between the funding source and overall quality rating for research reports after controlling for the type of research design; our research indicated that the effect size of the relationship was very small. The model for predicting research report quality from the funding source and research type allows us to predict only marginally better than chance (50.9%).

The more specific hypothesis that nutrition-related research reports that received industry funding were of lower quality than those funded by government sources was rejected. After controlling for the research type category, nutrition-related research reports acknowledging industry funding were no more likely to be of neutral or negative quality than those that received government funding. Stated in general terms, this means that in nutrition-related research, research reports that reported industry funding cannot be assumed to be of lower quality than those funded by government sources [24]. It is also worth noting that although 40.5% of research reports in the multiple funders category had industry funding, this category was also not significantly different and more closely approximated the quality ratings of the government funding category.

In our sample, industry funded more intervention research type reports than observation studies or reviews (approximately 74%, compared with 40%–56% for other funders). This funding is not surprising because the burden of proof of the effectiveness of nutrients and food products to support health claims and marketing materials falls on industry [47]. Because review research type reports were disproportionately rated as being of negative quality, the higher proportion of reports in this research type category affected the distribution of the quality of research reports funded by non-profit and university/hospital sources.

The appraisal of the quality of research reports is integral to the process when systematic reviews are conducted for the purpose of supporting the development of clinical practice guidelines, serving as the basis for public policy, or identifying research needs [27,47]. The peer-review process is intended to bring a high level of scrutiny to the appraisal process; however, even that level of expert review is not always sufficient to identify concerns. It is widely acknowledged that there are few if any perfect research studies and the limitations need to be carefully identified, discussed, and implications of limitations incorporated into the interpretation of the findings. It is therefore critical that quality appraisal of

Table 4. Primary research report areas of strengths and weaknesses based on Quality Criteria Checklist domain responses.¹

	Domain	Multiple Funders	Government	Industry	University/hospital	Non-profit	No Funding Reported
Q1	Research Question						
Q2	Subject Selection	Strength ²					Weakness
Q3	Comparable Group	Strength			Weakness		Strength
Q4	Withdrawals					Strength	Weakness
Q5	Blinding		Weakness ³			Strength	Weakness
Q6	Intervention/ Exposure		Strength		Weakness		Weakness
Q7	Outcome				Weakness		Weakness
Q8	Analysis						Weakness
Q9	Conclusion Support	Strength	Strength		Weakness		
210	Likelihood of Bias Due to Funding	Strength	Strength	Weakness	Weakness		

1. Each of the 10 Quality Criteria Checklist domain responses could be "yes", "no" or "unclear."

2. Strength indentified if P values based Z distribution of chi-square standardized residuals is <0.05 for: (a) greater than expected "yes" responses, (b) lower "no" responses, (c) lower "unclear" responses, (d) any combination of the above.

3. Weakness identified if P values based on Z distribution of chi-square standardized residuals is <0.05 for (a) lower than expected "yes" responses, (b) higher "no" responses, (c) higher "unclear" responses alone, or (d) lower "unclear" responses in combination for (b).

4. Cells with no value indicate that observed frequencies did not deviate from what would be expected if variables were independent.

doi:10.1371/journal.pone.0028437.t004

research reports is included in any synthesis of a body of research to avoid the possibility of magnifying any bias contained within that research. The intent is to rely more heavily on the higherquality research reports that provide the best insight into the true nature of a phenomenon when developing systematic reviews. This would be equally true for primary research as well as review research (synthesized into systematic reviews, meta-analysis, or narrative reviews). The goal is to rely more heavily on research reviews that have the lowest risk of bias. Evaluation of whether the results are likely to be biased by a researcher's funding source is part of the overall quality appraisal process; however, the process is intended to reflect the quality of all aspects of the research report.

The examination of the QCC domains in primary research that were strengths and weaknesses in the published research reports in the library database by funding source highlights the relative similarities and differences between research reports by funding category. The response for Question 10 (likelihood of bias due to funding) is a strength of multiple funders (of which 45% include industry funding) and government-funded research reports, while this was categorized as a weakness in both industry and university/ hospital funding. While this individual domain (likelihood of bias due to funding) is identified as a weakness in industry-funded research reports there were no other domains identified as either strengths or weaknesses for this type of funder. The large number of weaknesses identified in research reports from the not reported funding (7 weaknesses) and of university/hospital funding (5 weaknesses) categories identifies significant opportunities for improvement.

The present study supports the concept that although funding and research type are associated with the overall quality rating, simply knowing the funding source is insufficient to determine the quality of the research or its reporting.

Limitations and Strengths

Although our findings indicate that industry funding is not associated with lower research report quality, our results do not rule out other avenues for bias. Issues other than the rigor of the research and reporting such as selection of topics to be researched, specific research hypothesis tested, or selective reporting of research report results in subsequent research papers, and publication bias by journals continue to be factors in nutritionrelated and other research and warrant further attention [48,49]. These findings also reflect only the content that was included in the published research article. It is not known whether narrative review research reports in the review category had a systematic method of selecting the summarized research if that information was not included in the published research reports.

The small number of QCCs for reviews precluded analysis at the QCC domain level to identify opportunities for improvement in research reviews.

Although the large research sample used in this investigation included a broad range of topics, it is limited to nutrition-related research that is relevant to dietetics practice. The generalizability of these results to other nutrition topics and research is unknown.

Our research did not explore the accuracy of the financial disclosures. Explicit identification of the funding source was lacking for some research reports classified in the university/ hospital category, in which authors acknowledged support from their institution but it was unclear whether the support went beyond employment. In addition, our research did not determine the impact of the lack of sufficient funding. Only the not reported and the university/hospital funding categories had quality ratings that were significantly lower than government-funded research.

Other data indicate that there may be systematic underreporting of industry financial support [50]. Some bioethics researchers question whether the criteria for financial disclosure go far enough, and suggest that these criteria be even more explicit and disclose ultimate funding sources for organizations supported by industry [17,51,52]. Although we reviewed websites to characterize funding organizations, it is possible that not all instances of industry funding were identified.

This study has two important strengths: the breadth of the nutrition-related topics covered, and a sample size that allows for us to control for known confounders (i.e., type of research design) and conduct a more refined differentiation among six different types of funder categories.

Implications and Future Research

Review research reports had the largest opportunity for improvement in quality, regardless of the funding source. Because review research reports were consistently lower in quality and were frequently funded by nonprofits and industry, this may be an opportunity for these organizations and journal editorial staff to specify a preference for systematic reviews and meta-analyses, rather than more traditional narrative reviews.

The domains reflected as weaknesses shared by more than one funding category may represent the largest opportunity for improvement in nutrition-related research. Researchers may want to place additional emphasis on establishing and documenting group comparability or use of randomization, describing the intervention process, selecting and documenting appropriate outcomes measures, and likelihood of bias due to funding.

The present study lends support for the legitimate role of industry-funded research by dispelling a common concern that industry-funded research may be biased due to less rigorous research standards. Sensationalist headlines citing the direction of findings without also evaluating the scientific merit of the research are not helpful, and could lead to distrust of research in general without actually improving the research enterprise. Furthermore, if journal policies limit publication of industry-funded research, as some have suggested, the research is not readily available to inform the rest of the research enterprise or the public, which could limit the transparency of regulatory decisions [52]. Significant increases in federal funding would be required if industry-funded research were not considered as credible, because the greater burden for funding would be transferred to the government. Industry may want to consider increasing collaboratively funded research since the multiple funder category (of which 45% already included industry funding) had the greatest number of strengths and no weakness based on the individual QCC domain responses [Table 4]. However, it is critical to be vigilant so that all published research, regardless of the funding source, is of the highest possible quality.

Our research has implications for the media and consumers if the expectation or hope is that they judge the research on its merit, along with reporting the funding source [53]. Greater levels of commitment and research expertise are needed to evaluate the methods, statistics, and findings in a published research report to determine if there is a likelihood of bias in the research. The increased use of research summaries on websites makes it even more challenging for consumers to ascertain whether a research report has been peer reviewed and who funded the research and/ or website. In general, the research literacy of consumers and the media would need significant enhancement if this were to be the desired end state.

Additional studies in the following areas may be beneficial in the future:

- assessment of the impact of recently published standards for publishing manuscripts in nutrition-related research because other disciplines report mixed results [24,54–58];
- evaluation of the consistency in quality ratings among research quality appraisal tools;
- replication of the present study to determine if our findings are consistent in other systematic review databases (e.g., Cochrane or AHRQ databases); and
- determination of whether specific criteria in the checklists other than the Primary Research QCC used in this study confirm the domain areas most in need of improvements in nutrition-related research reports, and whether they are related to the direction of research findings (e.g., supportive of funders' interests).

Conclusion

Overall quality of research reports cannot be accurately predicted from the funding source after controlling for research design. Our results showed that there was no evidence of bias reflected by lower research report quality ratings that could be attributed to industry funding sources in food and nutrition research included in the systematic reviews published in the online ADA Evidence Analysis Library. The lowest overall quality ratings and the most individual QCC domain weaknesses were assigned to research reports that did not acknowledge any funding sources, followed by those that acknowledged university/hospital funding. Continued vigilance to evaluate the quality of all research regardless of funding source and to further understand other

References

- The National Academies (2003) Policy and procedures on committee composition and balance and conflicts of interest for committees used in development of reports. May 12. Available: http://www.nationalacademies. org/coi/index.html. Accessed 2010 Sep 9.
- Humphrey GF (1994) Scientific fraud: the McBride case-judgment. Med Sci Law 34: 299–306.
- Whitely WP, Rennie D, Hafner AW (1994) The scientific community's response to evidence of fraudulent publication. The Robert Slutsky case. JAMA 272: 170–173.
- Sox HC, Rennie D (2006) Research misconduct, retraction, and cleansing the medical literature: lessons from the Poehlman case. Ann Intern Med 144: 609–613.
- Fontanarosa PB, Flanagin A, DeAngelis CD (2005) Reporting conflicts of interest, financial aspects of research, and role of sponsors in funded studies. JAMA 294: 110–111.
- Miller FG, Brody H (2005) Viewpoint: professional integrity in industrysponsored clinical trials. Acad Med 80: 899–904.
- Davis JM, Chen N, Glick ID (2008) Issues that may determine the outcome of antipsychotic trials: industry sponsorship and extrapyramidal side effect. Neuropsychopharmacology 33: 971–975.
- Bekelman JE, Li Y, Gross CP (2003) Scope and impact of financial conflicts of interest in biomedical research: a systematic review. JAMA 289: 454–465.
- Lexchin J, Bero LA, Djulbegovic B, Clark O (2003) Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ 326: 1167–1170.
- Yao F, Singer M, Rosenfeld RM (2007) Randomized controlled trials in otolaryngology journals. Otolaryngol Head Neck Surg 137: 539–544.
- Bhandari M, Busse JW, Jackowski D, Montori V, Schüemann H, et al. (2004) Association between industry funding and statistically significant pro-industry findings in medical and surgical randomized trials. CMAJ 170: 477–480.
- Lesser LI, Ebbeling CB, Goozner M, Wypij D, Ludwig DS (2007) Relationship between funding source and conclusion among nutrition-related scientific articles. PLoS Med 4: e5.
- Vartanian LR, Schwartz MB, Brownell KD (2007) Effects of soft drink consumption on nutrition and health: a systematic review and meta-analysis. Am J Public Health 97: 667–675.

factors that affect research quality are warranted. There may be benefits of external funding on quality of research regardless of the funding source, in particular with projects that receive multiple funding sources.

Supporting Information

Supporting Information S1 Evidence Analysis Manual, Chapter 3. (PDF)

Supporting Information S2 Summary of Topics and Keywords from the Evidence Analysis Library database on February 2009 (expansion of Figure 5). (DOC)

Acknowledgments

The following individuals provided input by reviewing the proposal or manuscript: Douglas L. Weed, PhD, DLW Consulting; Jonathan B. VanGeest, PhD, Chair, Health Policy & Management, School of Community Health and Policy, Morgan State University; DeWitt C. Baldwin Jr, MD, Scholar-in-Residence, Accreditation Council for Graduate Medical Education; Matthew K. Wynia, MD, MPH, FACP, Director, The Institute for Ethics at the American Medical Association; and Lisa Spence, PhD, RD, Consultant to the American Dietetic Association. Betty Mueller, Phil Meister, and Matthew Fontaine entered the data. Tami Piemonte, MS, RD, Consultant to the American Dietetic Association collected and compared the critical appraisal instruments to the ADA Quality Criteria Checklist; and Antonia Acosta provided valuable editorial and administrative assistance.

Author Contributions

Conceived and designed the experiments: EFM JSP DSC PS. Performed the experiments: DSC JSP. Analyzed the data: JSP. Wrote the paper: EFM JSP DSC PS.

- Levine J, Gussow JD, Hastings D, Eccher A (2003) Authors' financial relationships with the food and beverage industry and their published positions on the fat substitute olestra. Am J Public Health 93: 664669.
- Brent R, Ehrlich GE, Gad SC, Caplan A, DcGregori T, et al. (2008) Scrutinizing industry-funded science: the crusade against conflicts of interest. New YorkNY: American Council on Science and Health.
- Rowe S, Alexander N, Clydesdale FM, Applebaum RS, Atkinson S, et al. (2009) Funding food science and nutrition research: financial conflicts and scientific integrity. Am J Clin Nutr 89: 1285–1291.
- 17. Resnik DB (2008) Hidden sources of private industry funding. Am J Bioeth 8: $60{-}1.$
- Public Library of Science (2009) PLoS policy on declaration and evaluation of competing interests. PLoS Medicine. Available: http://www.plosmedicine.org/ static/competing.action. Accessed 2011 Jan 22.
- Coughlin SS, Soskolne C, Goodman KW (1997) Case studies in public health ethics. Washington, DC: American Public Health Association.
- Martinson BC, Crain AL, Anderson MS, De Vries R (2009) Institutions' expectations for researchers' self-funding, federal grant holding, and private industry involvement: manifold drivers of self-interest and researcher behavior. Acad Med 84: 1491–1499.
- 21. Gluud LL (2006) Unravelling industry bias in clinical trials. Pain. 121: 175-176.
- Barden J, Derry S, McQuay HJ, Moore RA (2006) Bias from industry trial funding? A framework, a suggested approach, and a negative result. Pain 121: 207–218.
- Okike K, Kocher MS, Mehlman CT, Bhandari M (2007) Conflict of interest in orthopaedic research. An association between findings and funding in scientific presentations. J Bone Joint Surg Am 89: 608–613.
- Nkansah N, Nguyen T, Iraninezhad H, Bero L (2009) Randomized trials assessing calcium supplementation in healthy children: relationship between industry sponsorship and study outcomes. Public Health Nutr 12: 1931–1937.
- Katan MB (2007) Does industry sponsorship undermine the integrity of nutrition research? PLoS Med 4: e6.
- Thomas O, Thabane L, Douketis J, Chu R, Westfall AO, et al. (2008) Industry funding and the reporting quality of large long-term weight loss trials. Int J Obes (Lond) 32: 1531–1536.

- Lesser LI (2009) Reducing potential bias in industry-funded nutrition research. Am J Clin Nutr 90: 699–700; author reply 700701.
- Chung M, Balk EM, Ip S, Raman G, Yu WW, et al. (2009) Reporting of systematic reviews of micronutrients and health: a critical appraisal. Am J Clin Nutr 89: 1099–1113.
- Katrak P, Bialocerkowski AE, Massy-Westropp N, Kumar S, Grimmer KA (2004) A systematic review of the content of critical appraisal tools. BMC Med Res Methodol 4: 22.
- Sanderson S, Tatt ID, Higgins JP (2007) Tools for assessing quality and susceptibility to bias in observational studies in epidemiology: a systematic review and annotated bibliography. Int J Epidemiol 36: 666–676.
- Lohr KN (2004) Rating the strength of scientific evidence: relevance for quality improvement programs. Int J Qual Health Care 16: 9–18.
- Schulz KF, Altman DG, Moher D; CONSORT Group (0251) CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. PLoS Med. 2010 Mar 24;7(3):e100.
- Vandenbroucke JP, von Elm E, Altman DG, Gøtzsche PC, Mulrow CD, et al. (2007) STROBE Initiative.Strengthening the Reporting of Observational Studies in Epidemiology (STROBE)explanation and elaboration. PLoS Med. Oct 16;4(10):e297. Review. PMID:1794171534.
- von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, et al. (2007) STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Ann Intern Med. Oct 16;147(8):573-577. Erratum in: Ann Intern Med.2008 Jan 15;148(2): 168. PMID:17938396.
- 35. Strobe Statement: Strengthening the reporting of observational studies in epidemiology website. Available: http://www.strobe-statement.org/index. php?id=strobe-home. Accessed 2011 Oct 12.
- Armstrong R, Waters E, Moore L, Riggs E, Cuervo LG, et al. (2008) Improving the reporting of public health intervention research: advancing TREND and CONSORT. J Public Health (Oxf). Mar;30(1)103-109. Epub 2008 Jan 19. PMID:1820408637.
- Des Jarlais DC, Lyles C, Crepaz N (2004) TREND Group.Improving the reporting quality of nonrandomized evaluations of behavioral and public health interventions:the TREND statement. Am J Public Health, Mar;94(3):361-6. PMID:14998794.
- American Dietetic Association (2010) ADA Evidence Analysis Manual. Available: http://www.adaevidencelibrary.com/topic.cfm?cat=1155. Accessed 2011 Jan 11.
- Moher D, Liberati A, Tetzlaff J, Altman DG (2009) The PRISMA Group.N Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement. Open Med. 3(3)e123-e130. Epub 2009 Jul 21. No abstract available. PMID:2160304540.
- Prisma: Transparent Reporting of Systematic Reviews and Meta-Analyses website. Available: http://www.prisma-statement.org/statement.htm. Accessed 2011 Oct, 12.
- Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, et al. (2000) Metaanalysis of observational studies in epidemiology: a proposal for reporting. Meta-

analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA. Apr 19;283(15):2008-2012. Review. PMID:1078967042.

- 42. Shea BJ, Hamel C, Wells GA, Bouter LM, Kristjansson E, et al. (2009) AMSTAR is a reliable and valid measurement tool to assess the methodological quality of systematic reviews. J Clin Epidemiol, Oct;62(10):1013-1020. Epub 2009 Feb 20. PMID:1923060639.
- Livingston EH, Elliot A, Hynan L, Cao J (2009) Effect size estimation: a necessary component of statistical analysis. Arch Surg 144: 706–712.
- Clifford TJ, Barrowman NJ, Moher D (2002) Funding source, trial outcome and reporting quality: are they related? Results of a pilot study. BMC Health Serv Res 2: 18.
- Kleinbaum DG, Klein M (2002) Logistic regression. 2nd ed. New York, NY: Springer-Verlag.
- Tabachnick BG, Fidell LS (2006) Using multivariate statistics. 5th ed. Boston, MA:Allyn & Bacon.
- U.S. Food and Drug Administration (2009) Guidance for industry: evidencebased review system for the scientific evaluation of health claims. November 30. Available: http://www.fda.gov/Food/GuidanceComplianceRegulatoryInfor mation/GuidanceDocuments/FoodLabelingNutrition/ucm073332.htm. Accessed 2011 Aug 29.
- Cope MB, Allison DB (2010) White hat bias: examples of its presence in obesity research and a call for renewed commitment to faithfulness in research reporting. Int J Obes (Lond) 34:84-88; discussion 83.
- Barbui C, Cipriani A (2007) Publication bias in systematic reviews. Arch Gen Psychiatry 64: 868.
- Sharp RK, Scott AL, Landy DC, Kicklighter LA (2008) Who is buying bioethics research? Am J Bioeth 8:54-58; discussion W51-52.
- Schwartz RS, Curfman GD, Morrissey S, Drazen JM (2008) Full disclosure and the funding of biomedical research. N Engl J Med 358: 1850–1851.
- Elliott C (2005) Should journals publish industry-funded bioethics articles? Lancet 366: 422–424.
- Cook DM, Boyd EA, Grossmann C, Bero LA (2007) Reporting science and conflicts of interest in the lay press. PLoS One 2: e1266.
- Brand RA (2009) Standards of reporting: the CONSORT, QUORUM, and STROBE guidelines. Clin Orthop Relat Res 467: 1393–1394.
- Vandenbroucke JP (2009) STREGA, STROBE, STARD, SQUIRE, MOOSE, PRISMA, GNOSIS, TREND, ORION, COREQ, QUOROM, REMARK... and CONSORT: for whom does the guideline toll? J Clin Epidemiol 62: 594–596.
- Verbeek J (2008) Moose Consort Strobe and Miami Stard Remark or how can we improve the quality of reporting studies. Scand J Work Environ Health 34: 165–167.
- Alvarez F, Meyer N, Gourraud PA, Paul C (2009) CONSORT adoption and quality of reporting of randomized controlled trials: a systematic analysis in two dermatology journals. Br J Dermatol 161: 1159–1165.
- Moher D, Schulz KF, Altman D (2005) The CONSORT Statement: revised recommendations for improving the quality of reports of parallel-group randomized trials 2001. Explore (NY) 1: 40–45.